FrancophonIA/ELRC3.0 huggingface dataset:
English: If you are allergic to talazoparib or any of the other ingredients of this medicine (listed in section 6).
Croatian: Nemojte uzimati lijek Talzenna - Ako ste alergični na talazoparib ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: You should not become pregnant while taking Talzenna.
Croatian: - Ne smijete zatrudnjeti dok uzimate lijek Talzenna.
English: No talazoparib dose adjustments are required when co-administered with rifampin.
Croatian: Prilagodbe doze talazopariba nisu potrebne kada se talazoparib istodobno primjenjuje s rifampinom.
English: Additional findings at higher exposures included dose-dependent increase in apoptosis/necrosis in the gastrointestinal (GI) tract, liver and ovary.
Croatian: Dodatni rezultati dobiveni pri većim izloženostima uključivali su o dozi ovisno povećanje apoptoze/nekroze u gastrointestinalnom traktu, jetri i jajniku.
English: What Talzenna is used for
Croatian: Za što se Talzenna koristi
English: Talazoparib is a substrate of P-gp and BCRP transporters.
Croatian: Talazoparib je supstrat za prijenosnike P-gp i BCRP.
English: The median accumulation ratio of talazoparib following repeated oral administration of 1 mg once daily was in the range of 2.3 to 5.2.
Croatian: Medijan omjera akumulacije talazopariba nakon ponavljane peroralne primjene doze od 1 mg jednom na dan bio je u rasponu od 2,3 do 5,2.
English: Abbreviations: BRCA=breast cancer susceptibility gene; ER=estrogen receptor; HER2=human epidermal growth factor receptor 2; N=number of patients; n=number of patients in category; PgR=progesterone receptor.
Croatian: Kratice: BRCA=gen sklonosti za rak dojke (engl. breast cancer susceptibility gene); ER=estrogenski receptor; HER2=receptor humanog epidermalnog čimbenika rasta 2; N=broj bolesnika; n= broj bolesnika u kategoriji; PgR=progesteronski receptor.
English: No adverse reactions were reported in one patient who accidentally self-administered thirty 1-mg capsules of talazoparib on Day 1 and was immediately treated with gastric decontamination.
Croatian: Nije zabilježena nijedna nuspojava u jednog bolesnika koji je slučajno uzeo trideset kapsula talazopariba od 1 mg 1. dana i koji je odmah bio podvrgnut dekontaminaciji želuca.
English: Precautions should be taken to routinely monitor haematology parameters and signs and symptoms associated with anaemia, leucopenia/neutropenia, and/or thrombocytopenia in patients receiving talazoparib.
Croatian: Potrebno je poduzeti mjere kako bi se rutinski pratili hematološki parametri te znakovi i simptomi povezani s anemijom, leukopenijom/neutropenijom i/ili trombocitopenijom u bolesnika koji primaju talazoparib.
English: Women of childbearing potential should not become pregnant while receiving Talzenna and should not be pregnant at the beginning of treatment.
Croatian: Žene reproduktivne dobi ne smiju zatrudnjeti dok uzimaju lijek Talzenna i ne smiju biti trudne na početku liječenja.
English: Adverse reactions based on pooled dataset from 5 studies (N=494) System organ class Frequency Preferred term
Croatian: Tablica 3. Nuspojave temeljene na objedinjenim nizovima podataka iz 5 ispitivanja (N = 494) Klasifikacije organskih sustava Učestalost Preporučeni pojam
English: PARP inhibitors (PARPi) exert cytotoxic effects on cancer cells by 2 mechanisms, inhibition of PARP catalytic activity and by PARP trapping, whereby PARP protein bound to a PARPi does not readily dissociate from a DNA lesion, thus preventing DNA repair, replication, and transcription, thereby resulting in apoptosis and/or cell death.
Croatian: Inhibitori PARP-a (PARPi) imaju citotoksične učinke na stanice raka primjenom 2 mehanizma: inhibicije katalitičke aktivnosti PARP-a i hvatanja PARP-a, pri čemu se protein PARP koji je vezan na PARPi ne odvaja lako od DNK lezije, čime se sprječava popravak, replikacija i transkripcija DNK što rezultira apoptozom i/ili smrću stanice.
English: A highly effective method of contraception is required for female patients during treatment with Talzenna, and for at least 7 months after completing therapy.
Croatian: Potrebna je visokoučinkovita metoda kontracepcije za bolesnice tijekom liječenja lijekom Talzenna i najmanje 7 mjeseci nakon završetka terapije.
English: In repeat-dose toxicity studies in rats and in dogs, the main findings at subtherapeutic exposures included bone marrow hypocellularity with dose-dependent decrease in haematopoietic cells, depletion of lymphoid tissue in multiple organs and atrophy and/or degenerative changes in testes, epididymis and seminiferous tubules.
Croatian: U ispitivanjima toksičnosti ponovljene doze u štakora i pasa glavni rezultati pri subterapijskim izloženostima uključivali su hipocelularnost koštane srži sa smanjenjem u hematopoetskim stanicama ovisnim o dozi, depleciju limfatičkog tkiva u više organa i atrofiju i/ili degenerativne promjene u testisima, epididimisu i seminifernim tubulama.
English: Developmental toxicology
Croatian: Razvojna toksikologija
English: Myelosuppression-related adverse events associated with dose modifications were reported for up to approximately 30% of patients in the talazoparib 1 mg/day population and those associated with permanent study drug discontinuation were reported for less than 1% of patients.
Croatian: Štetni događaji povezani s mijelosupresijom koji prate promjene doze zabilježeni su u do približno 30 % bolesnika u populaciji liječenoj talazoparibom u dozi od 1 mg/dan, a oni koji prate trajni prekid primjene ispitivanog lijeka zabilježeni su u manje od 1 % bolesnika.
English: Other P-gp inducers (including but not limited to carbamazepine, phenytoin, and St. John's wort) may decrease talazoparib exposure.
Croatian: Drugi induktori P-gp-a (uključujući, ali ne ograničavajući se na karbamazepin, fenitoin i gospinu travu) mogu smanjiti izloženost talazoparibu.
English: Patients should be selected for the treatment of breast cancer with Talzenna based on the presence of deleterious or suspected deleterious germline BRCA mutations determined by an experienced laboratory using a validated test method.
Croatian: Bolesnici trebaju biti odabrani za liječenje raka dojke lijekom Talzenna na temelju prisutnosti štetnih ili sumnje na štetne mutacije gena BRCA u zametnim stanicama koje je utvrdio iskusan laboratorij primjenom potvrđene metode testiranja.
English: Supportive care with or without blood and/or platelet transfusions and/or administration of colony stimulating factors may be used as appropriate.
Croatian: Prema potrebi se može primijeniti suportivna skrb sa ili bez transfuzija krvi i/ili trombocita i/ili primjena čimbenika stimulacije kolonija.
English: Concomitant use of strong P-gp inhibitors (including but not limited to amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, and verapamil) should be avoided.
Croatian: Potrebno je izbjegavati istodobnu primjenu jakih inhibitora P-gp-a (uključujući, ali ne ograničavajući se na: amiodaron, karvedilol, klaritromicin, kobicistat, darunavir, dronedaron, eritromicin, indinavir, itrakonazol, ketokonazol, lapatinib, lopinavir, propafenon, kvinidin, ranolazin, ritonavir, sakvinavir, telaprevir, tipranavir i verapamil).
English: To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered (Table 2).
Croatian: Prilikom liječenja nuspojava potrebno je razmotriti privremeni prekid liječenja ili smanjenje doze na temelju težine i kliničke slike (tablica 2).
English: A population PK analysis was conducted using data from 490 patients with cancer to evaluate the impact of age (ranging from 18 to 88 years), sex (53 males and 437 females), and body weight (ranging from 35.7 kg to 162 kg) on the PK of talazoparib.
Croatian: Analiza populacijske farmakokinetike provedena je korištenjem podataka od 490 bolesnika koji boluju od raka kako bi procijenila utjecaj dobi (u rasponu od 18 do 88 godina), spola (53 muškarca i 437 žena) i tjelesne težine (u rasponu od 35,7 kg do 162 kg) na farmakokinetiku talazopariba.
English: Forest plot of PFS analyses for key subgroups - EMBRACA study
Croatian: Grafikon raspona pouzdanosti analiza PFS-a za ključne podskupine - ispitivanje EMBRACA
English: Patient demographic, baseline, and disease characteristics were generally similar between the study treatment arms (see Table 4).
Croatian: Općenito su demografske karakteristike, početne karakteristike i karakteristike bolesti bolesnika bile slične među liječenim skupinama u ispitivanju (vidjeti tablicu 4).
English: Since the use of hormonal contraception is not recommended if you have breast cancer, you should use two non-hormonal contraception methods.
Croatian: Budući se ne preporučuje primjena hormonske kontracepcije ako imate rak dojke, trebate koristiti dvije nehormonalne kontracepcije.
English: The dose may be lowered to 0.75 mg (taken as three 0.25-mg capsules) once daily, or 0.5 mg (two 0.25-mg capsules) once daily, or 0.25 mg (one 0.25-mg capsule) once daily.
Croatian: Doza se može smanjiti na 0,75 mg (uzimaju se tri kapsule od 0,25 mg) jednom na dan ili na 0,5 mg (uzimaju se dvije kapsule od 0,25 mg) jednom na dan ili na 0,25 mg (uzima se jedna kapsula od 0,25 mg) jednom na dan.
English: St. John's wort (Hypericum perforatum) - a herbal remedy used to treat mild depression and anxiety.
Croatian: - Gospina trava (Hypericum perforatum) - biljni lijek koji se koristi u liječenju blage depresije i tjeskobe.
English: A risk to breast-fed children cannot be excluded and therefore breast-feeding is not recommended during treatment with Talzenna and for at least 1 month after the final dose.
Croatian: Rizik za dojenčad ne može se isključiti te se stoga dojenje ne preporučuje tijekom liječenja lijekom Talzenna i tijekom najmanje 1 mjesec nakon zadnje doze.
English: Common (may affect up to 1 in 10 people) Alteration in taste (dysgeusia) Indigestion
Croatian: Često (mogu se javiti u manje od 1 na 10 osoba) - Promjena okusa (disgeuzija) - Loša probava
English: Patients were required to have received treatment with an anthracycline and/or a taxane (unless contraindicated) in the neoadjuvant, adjuvant and/or metastatic setting.
Croatian: Bolesnici su trebali primiti liječenje antraciklinom i/ili taksanom (osim ako je kontraindiciran) u neoadjuvantnom, adjuvantnom i/ili metastatskom okruženju.
English: In particular, the following may increase the risk of side effects with Talzenna: Amiodarone, carvedilol, dronedarone, propafenone, quinidine, ranolazine and verapamilgenerally used to treat heart problems.
Croatian: Posebice, sljedeći lijekovi mogu povećati rizik od nuspojava s lijekom Talzenna: - Amiodaron, karvedilol, dronedaron, propafenon, kvinidin, ranolazin i verapamil - uglavnom se koriste za liječenje srčanih problema.
English: Talzenna 1 mg hard capsules EU/1/19/1377/005
Croatian: Talzenna 1 mg tvrde kapsule EU/1/19/1377/005
English: The most common (≥ 25%) adverse reactions in patients receiving talazoparib in these clinical studies were fatigue (57.1%), anaemia (49.6%), nausea (44.3%), neutropenia (30.2%), thrombocytopenia (29.6%), and headache (26.5%).
Croatian: Najčešće (≥ 25 %) nuspojave u bolesnika koji su primali talazoparib u ovim kliničkim ispitivanjima bile su: umor (57,1 %), anemija (49,6 %), mučnina (44,3 %), neutropenija (30,2 %), trombocitopenija (29,6 %) i glavobolja (26,5 %).
English: Insufficient data are available to estimate the impact of severe renal impairment on talazoparib CL/F in this patient population.
Croatian: Nema dovoljno podataka da bi se procijenio utjecaj teškog oštećenja funkcije bubrega na prividni peroralni klirens talazopariba u ovoj populaciji bolesnika.
English: Manufacturer Excella GmbH & Co. KG Nürnberger Strasse 12 90537 Feucht Germany
Croatian: KG Nürnberger Strasse 12 90537 Feucht Njemačka
English: Concomitant use of strong P-gp inhibitors during treatment with talazoparib should be avoided.
Croatian: Treba izbjegavati istodobnu primjenu jakih inhibitora P-gp-a tijekom liječenja talazoparibom.
English: Talzenna may have a minor influence on the ability to drive and use machines.
Croatian: Lijek Talzenna može malo utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
English: Since the use of hormonal contraception is not recommended in patients with breast cancer, two non-hormonal and complementary contraception methods should be used (see section 4.6).
Croatian: Budući da se ne preporučuje upotreba hormonske kontracepcije u bolesnica s rakom dojke, trebale bi se koristiti dvije nehormonalne i komplementarne metode kontracepcije (vidjeti dio 4.6).
English: Abbreviations: BICR=blinded independent central review; CI=confidence interval; CMH=CochranMantel-Haenszel; CR=complete response; IQR=interquartile range; ITT=intent-to-treat; ORR=objective response rate; OS=overall survival; PR=partial response; RECIST 1.1=Response Evaluation Criteria in Solid Tumors version 1.1. a. Hazard ratio was based on stratified Cox regression model with treatment as the only covariate
Croatian: Kratice: BICR=slijepa neovisna centralna procjena (engl. blinded independent central review); CI=interval pouzdanosti (engl. confidence interval); CMH=Cochran-Mantel-Haenszel; CR=potpuni odgovor (engl. complete response); IQR=interkvartilni raspon (engl. interquartile range); ITT=populacija predviđena za liječenje (engl. intent-to-treat); ORR=stopa objektivnog odgovora (engl. objective response rate); OS=ukupno preživljenje (engl. overall survival); PR=djelomičan odgovor (engl. partial response); RECIST 1.1=Kriteriji za procjenu odgovora kod solidnih tumora, verzija 1.1. (engl.
English: Following repeated daily dosing of 1 mg talazoparib to patients, the geometric mean (% coefficient of variation [CV%]) area under the plasma concentration-time curve (AUC) and maximum observed plasma concentration (Cmax) of talazoparib at steady-state was in the range of 126 (107) ng•hr/mL to 208 (37) ng•hr/mL and 11 (90) ng/mL to 19 (27) ng/mL, respectively.
Croatian: Nakon što je u bolesnika primijenjena ponavljana dnevna doza od 1 mg talazopariba, geometrijska srednja vrijednost (% koeficijent varijacije) područja ispod krivulje koncentracija u plazmi-vrijeme (AUC) i maksimalne zabilježene koncentracije talazopariba u plazmi (Cmax) u stanju dinamičke ravnoteže kretala se u rasponu od 126 (107) ng•h/ml do 208 (37) ng•h/ml, odnosno od 11 (90) ng/ml do 19 (27) ng/ml.
English: Population PK analysis indicates that co-administration of acid-reducing agents including proton pump inhibitors and histamine receptor 2 antagonists (H2RA), or other acid-reducing agents had no significant impact on the absorption of talazoparib.
Croatian: Analiza populacijske farmakokinetike pokazuje da istodobna primjena lijekova koji smanjuju kiselinu, uključujući inhibitore protonske pumpe i antagoniste histaminskih receptora tipa 2 (H2RA) ili druge lijekove koji smanjuju kiselinu, nije imala značajan utjecaj na apsorpciju talazopariba.
English: In an embryo-foetal development study in rats, talazoparib resulted in embryo-foetal death, foetal malformation (depressed eye bulge, small eye, split sternebrae, fused cervical vertebral arch) and structural variations in bones at a maternal systemic AUC24 exposure approximately 0.09-fold the relevant human exposure at the recommended dose.
Croatian: U ispitivanju embrio-fetalnog razvoja u štakora talazoparib je doveo do embrio-fetalne smrti, malformacija fetusa (uvučena očna jabučica, malo oko, razdvojene sternebre, srašten luk kralješka vrata) i strukturne varijacije u kostima pri majčinoj sistemskoj izloženosti AUC24 približno 0,09 puta većoj od značajne izloženosti ljudi pri preporučenoj dozi.
English: Polyvinyl chloride/polyvinylidene chloride (PVC/PVdC) perforated unit dose blister with an aluminum peel off foil lidding.
Croatian: Polivinilkloridni/poliviniliden kloridni (PVC/PVdC) perforirani blister s jediničnim dozama zatvoren s aluminijskom folijom na otvoru koja se može odlijepiti.
English: 1 mg (one 1 mg capsule) once daily
Croatian: 1 mg (jedna kapsula od 1 mg) jednom na dan
English: The effect of talazoparib on cardiac repolarisation was evaluated using time-matched electrocardiograms (ECGs) in assessing the relationship between the change of the QT interval corrected for heart rate (QTc) from baseline and the corresponding plasma talazoparib concentrations in 37 patients with advanced solid tumours.
Croatian: Učinak talazopariba na repolarizaciju srca procijenjen je primjenom s vremenom povezanih promjena EKG-a pri utvrđivanju veze između promjene QT-intervala korigiranog prema srčanoj frekvenciji (QTc) na početku liječenja i odgovarajućih koncentracija talazopariba u plazmi u 37 bolesnika s uznapredovalim solidnim tumorima.
English: Treatment of cancer cell lines that are harbouring defects in DNA repair genes with talazoparib single agent leads to increased levels of γH2AX, a marker of double stranded DNA breaks, and results in decreased cell proliferation and increased apoptosis.
Croatian: Liječenje staničnih linija raka koje imaju anomalije u genima za popravak DNK samo talazoparibom dovodi do povećanih razina γH2AX, pokazatelja lomova dvolančane DNK, i uzrokuje smanjenu staničnu proliferaciju i povećanu apoptozu.
English: No dose adjustment is required for patients with mild renal impairment (60 mL/min ≤ creatinine clearance [CrCl] < 90 mL/min).
Croatian: Nije potrebna prilagodba doze u bolesnika s blagim oštećenjem bubrega (60 ml/min ≤ klirens kreatinina [CrCl] < 90 ml/min).
English: Kaplan-Meier curves of PFS - EMBRACA study
Croatian: Kaplan-Meierove krivulje PFS-a - ispitivanje EMBRACA
English: Pack sizes: cartons of 30 × 1 capsules, or 60 × 1 capsules, or 90 × 1 capsules in unit dose blisters.
Croatian: Veličine pakiranja: kutije s 30 × 1 kapsulom ili 60 × 1 kapsulom ili 90 × 1 kapsulom u blisterima s jediničnim dozama.
English: Population pharmacokinetic (PK) analysis has also shown that concomitant use of strong P-gp inhibitors increased talazoparib exposure by 45%, relative to talazoparib given alone.
Croatian: Analiza populacijske farmakokinetike isto je tako pokazala da je istodobna primjena jakih inhibitora P-gp-a povećala izloženost talazoparibu za 45 %, u usporedbi s talazoparibom kada se primjenjuje sam.
English: Talzenna has not been studied in patients with severe renal impairment (CrCl < 30 mL/min) or patients requiring haemodialysis.
Croatian: Lijek Talzenna nije ispitivan u bolesnika s teškim oštećenjem bubrega (CrCl < 30 ml/min) ili u bolesnika kojima je potrebna hemodijaliza.
English: In vitro, talazoparib did not inhibit any of the major uridine-diphosphate glucuronosyltransferase (UGT) isoforms (1A1, 1A4, 1A6, 1A9, 2B7, and 2B15) at clinically relevant concentrations.
Croatian: In vitro, talazoparib nije inhibirao niti jedan od glavnih izoformi uridin-difosfatglukuronoziltransferaze (UGT) (1A1, 1A4, 1A6, 1A9, 2B7 i 2B15) pri klinički značajnim koncentracijama.
English: Median PFS=8.6 months 95% CI (7.2, 9.3)
Croatian: Medijan PFS-a=8,6 mjeseci 95% CI (7,2; 9,3)
English: Talzenna may cause foetal harm when administered to a pregnant woman.
Croatian: Lijek Talzenna može izazvati oštećenja fetusa kada se daje trudnici.
English: Talzenna may only be used in patients with moderate or severe hepatic impairment if the benefit outweighs the potential risk, and the patient should be carefully monitored for hepatic function and adverse events.
Croatian: Lijek Talzenna smije se primjenjivati u bolesnika s umjerenim ili teškim oštećenjem jetre samo ako korist nadmašuje mogući rizik, dok je potrebno pozorno pratiti funkciju jetre i moguću pojavu štetnih događaja u bolesnika.
English: Since the use of hormonal contraception is not recommended in patients with breast cancer, two non-hormonal and complementary contraception methods should be used.
Croatian: Budući da se ne preporučuje upotreba hormonske kontracepcije u bolesnica s rakom dojke, trebale bi se koristiti dvije nehormonalne i komplementarne metode kontracepcije.
English: You will have regular blood tests during treatment with Talzenna to check your blood cells (white blood cells, red blood cells, and platelets).
Croatian: Tijekom terapije lijekom Talzenna podvrgnut ćete se redovitim krvnim pretragama kako bi se provjerile Vaše krvne stanice (leukociti, eritrociti i trombociti).
English: Agents that may affect talazoparib plasma concentrations
Croatian: Lijekovi koji mogu utjecati na koncentracije talazopariba u plazmi
English: The mean (±standard deviation) terminal plasma half-life of talazoparib was 90 (±58) hours and the population mean (inter-subject variability) apparent oral clearance (CL/F) was 6.5 (31%) L/h in cancer patients.
Croatian: Srednja vrijednost (± standardna devijacija) terminalnog poluvijeka talazopariba u plazmi iznosila je 90 (± 58) sati, a srednja vrijednost populacijskog (interindividualna varijabilnost) prividnog peroralnog klirensa iznosila je 6,5 (31 %) l/h u bolesnika koji boluju od raka.
English: Talzenna is not recommended during pregnancy or for women of childbearing potential not using contraception (see section 4.4).
Croatian: Ne preporučuje se koristiti lijek Talzenna tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju (vidjeti dio 4.4).
English: Talazoparib was clastogenic in an in vitro chromosomal aberration assay in human peripheral blood lymphocytes and in an in vivo bone marrow micronucleus assay in rats but not mutagenic in Ames assay (see section 5.3), and may cause foetal harm when administered to a pregnant woman.
Croatian: Talazoparib je bio klastogen u in vitro testu aberacije kromosoma u humanim limfocitima periferne krvi i u in vivo mikronukleus testu koštane srži u štakora, ali nije bio mutagen u Amesovom testu (vidjeti dio 5.3), te može izazvati oštećenja fetusa kada se daje trudnici.
English: In vitro, talazoparib was not an inhibitor of cytochrome (CYP)1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5 or inducer of CYP1A2, CYP2B6, or CYP3A4 at clinically relevant concentrations.
Croatian: In vitro, talazoparib nije bio inhibitor citokroma (CYP)1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ili CYP3A4/5 niti induktor CYP1A2, CYP2B6 ili CYP3A4 pri klinički značajnim koncentracijama.
English: What Talzenna is and what it is used for
Croatian: Što je Talzenna i za što se koristi
English: Women of childbearing potential must use highly effective forms of contraception (see section 4.4) prior to starting treatment with talazoparib, during treatment, and for 7 months after stopping treatment with talazoparib.
Croatian: Žene reproduktivne dobi moraju koristiti visokoučinkovite oblike kontracepcije (vidjeti dio 4.4) prije početka liječenja, tijekom liječenja i tijekom 7 mjeseci nakon završetka liječenja talazoparibom.
English: It is unknown whether talazoparib is excreted in human breast milk.
Croatian: Nije poznato izlučuje li se talazoparib u majčino mlijeko.
English: Of the 431 patients randomised in the EMBRACA study, 408 (95%) were centrally confirmed to have a deleterious or suspected deleterious gBRCAm using a clinical trial assay; out of which 354 (82%) were confirmed using the BRACAnalysis CDx®.
Croatian: Za 408 (95 %) od 431 bolesnika randomiziranog u ispitivanje EMBRACA bilo je centralno potvrđeno da imaju štetan ili sumnju na štetan gBRCAm primjenom testa kliničkog ispitivanja, dok je za 354 (82 %) njih isto bilo potvrđeno primjenom testa BRACAnalysis CDx
English: Randomised Phase 3 study EMBRACA
Croatian: Faza 3 randomiziranog ispitivanja EMBRACA
English: A pregnancy test should be performed on all women of childbearing potential prior to treatment (see section 4.4).
Croatian: Sve žene reproduktivne dobi moraju napraviti test na trudnoću prije liječenja (vidjeti dio 4.4).
English: Talazoparib Chemotherapy
Croatian: Talazoparib Kemoterapija
English: Contraception in women of childbearing potential
Croatian: Kontracepcija u žena reproduktivne dobi